This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gortner, L.
Right arrow Articles by Kuhls, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gortner, L.
Right arrow Articles by Kuhls, E.
Related Collections
Right arrow Premature & Newborn

PEDIATRICS Vol. 102 No. 5 November 1998, pp. 1153-1160

Early Versus Late Surfactant Treatment in Preterm Infants of 27 to 32 Weeks' Gestational Age: A Multicenter Controlled Clinical Trial

Received Oct 20, 1997; accepted May 5, 1998.

Ludwig Gortner*, Roland R. WauerDagger , Hannes HammerDagger , Gerd-J. Stock§, Friedhelm Heitmann§, Hans L. Reiterparallel , Peter G. Kühlparallel , Jens C. Möller*, Hans-J. Friedrich*, Irwin Reiss*, Roland Hentschel, Gerhard Jorch, Gertrud Hieronimi#, and Eckhard Kuhls#

From the * University Children's Hospital, Lübeck; the Dagger  University Children's Hospital Charité, Berlin; the § Community Hospital, Dortmund; the parallel  University Children's Hospital, Giessen; the  University Children's Hospital, Münster; and # Olgahospital, Pediatric Center, Stuttgart, Germany.

Objective.  To investigate whether early (<1 hour after birth) surfactant administration would be superior to late treatment (2-6 hours after birth) in preterm infants.

Study Design.  Randomized controlled multicenter clinical trial.

Patients and Methods.  Prenatal randomization of all infants of 27 to 32 weeks' gestational age stratified by center after parental informed consent. Early treatment: 100 mg/kg body weight bovine surfactant (SF-RI1, Alveofact; Dr K. Thomae, Biberach, Germany) to infants requiring intubation after birth. Late treatment: identical dosage to infants requiring intubation up to 6 hours of age with the fraction of inspired oxygen >0.4 at 2 to 6 hours after birth. Primary endpoint: the time on mechanical ventilation. Main secondary endpoints: mortality, bronchopulmonary dysplasia, intraventricular hemorrhage >= grade III, and periventricular leukomalacia. Sample size calculation: at least 280 infants to prove superiority of either approach (alpha = 0.05; beta  = 0.90).

Results.  Enrollment of 317 infants, 154 randomized to early surfactant treatment, 163 to late surfactant treatment. Study infants (all following data intent-to-treat groups: early versus late surfactant) were similar with respect to: gestational age, 29.5 ± 1.6 weeks versus 29.7 ± 1.6 weeks; birth weight, 1227 ± 367 g versus 1269 ± 334 g; and the rate of prenatal corticosteroids, 79.9% versus 72.8%. Duration of mechanical ventilation: 3 days (0-8) versus 2 days (0-6) (median, interquartile); further outcome variables: death or bronchopulmonary dysplasia (day 28) 25.9% versus 23.9%, mortality 3.2% versus 1.8%, intraventricular hemorrhage >= grade III 6.5% versus 3.7%, and periventricular leukomalacia 5.2% versus 5.5% not differing statistically.

Conclusion.  In preterm infants with a high rate of prenatal glucocorticoids, early surfactant administration was not found to be superior to late treatment in terms of relevant outcome variables.  Key words:  respiratory distress syndrome, preterm infants, prenatal glucocorticoids, surfactant treatment, mechanical ventilation, bronchopulmonary dysplasia.




This article has been cited by other articles:


Home page
 PediatricsHome page
W. A. Engle and and the Committee on Fetus and Newborn
Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate
Pediatrics, February 1, 2008; 121(2): 419 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. Ghodrat
Lung surfactants.
Am. J. Health Syst. Pharm., August 15, 2006; 63(16): 1504 - 1521.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
P. D Reiter, C. Sims, L. Harmes, J. Paisley, A. A Rosenberg, and R. J Valuck
Calfactant Sterility in Multiple Doses from Single-Use Vials
Ann. Pharmacother., September 1, 2003; 37(9): 1219 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. Kattwinkel, B. T. Bloom, P. Delmore, C. Glick, D. Brown, S. Lopez, L. Willett, E. A. Egan, M. Conaway, and J. Patrie
High-Versus Low-Threshold Surfactant Retreatment For Neonatal Respiratory Distress Syndrome
Pediatrics, August 1, 2000; 106(2): 282 - 288.
[Abstract] [Full Text]